Achille E Tchalla1,2,3,4, Gregory A Wellenius5, Farzaneh A Sorond6, Margaret Gagnon1, Ikechukwu Iloputaife1, Thomas G Travison1,2,3, Thierry Dantoine4, Lewis A Lipsitz1,2,3. 1. Institute for Aging Research, Hebrew SeniorLife, Boston, Massachusetts. 2. Beth Israel Deaconess Medical Center, Boston, Massachusetts. 3. Harvard Medical School, Boston, Massachusetts. 4. Department of Geriatric Medicine, Limoges University, Limoges, France. 5. Brown University School of Public HealthProvidence, Rhode Island. 6. Department of Neurology, Stroke Division, Brigham and Women's Hospital, Boston, Massachusetts.
Abstract
BACKGROUND: Elevated plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) is a presumed marker of endothelial dysfunction, both in the brain and systemic circulation. Impairments in memory and cognition have been associated with cardiovascular diseases, but little is known about their relationships to abnormal cerebral endothelial function. METHODS: We studied the cross-sectional association between sVCAM-1 and markers of cerebrovascular hemodynamics and cognitive function in 680 community-dwelling participants in the MOBILIZE Boston Study, aged 65 years and older. Cognitive function was assessed using the Hopkins Verbal Learning Memory Test and Trail Making Tests (TMTs) A and B. Global cognitive impairment was defined as Mini-Mental State Examination (MMSE) score less than 24. sVCAM-1 was measured by ELISA assay. Beat-to-beat blood flow velocity (BFV) and cerebrovascular resistance (CVR = mean arterial pressure / BFV) in the middle cerebral artery were assessed at rest by transcranial Doppler ultrasound. RESULTS: sVCAM-1 concentrations were higher among participants with an MMSE score <24 versus ≥24 (1,201±417 vs 1,122±494ng/mL). In regression models adjusted for sociodemographic characteristics and health conditions, increasing levels of sVCAM-1 were linearly associated with higher resting CVR (p = .006) and lower performance on the Hopkins Verbal Learning Memory (immediate recall and delayed recall) and adjusted TMT B tests (p < .05). Higher levels of sVCAM-1 were also associated with global cognitive impairment on the MMSE (odds ratio = 3.9; 95% confidence interval: 1.4-10.9; p = .011). CONCLUSIONS: In this cohort of elderly participants, we observed a cross-sectional association between elevated sVCAM-1 levels and both cognitive impairment and increased cerebrovascular resistance. Longitudinal studies are needed to determine whether elevated sVCAM-1 is a cause or consequence of cerebrovascular damage.
BACKGROUND: Elevated plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) is a presumed marker of endothelial dysfunction, both in the brain and systemic circulation. Impairments in memory and cognition have been associated with cardiovascular diseases, but little is known about their relationships to abnormal cerebral endothelial function. METHODS: We studied the cross-sectional association between sVCAM-1 and markers of cerebrovascular hemodynamics and cognitive function in 680 community-dwelling participants in the MOBILIZE Boston Study, aged 65 years and older. Cognitive function was assessed using the Hopkins Verbal Learning Memory Test and Trail Making Tests (TMTs) A and B. Global cognitive impairment was defined as Mini-Mental State Examination (MMSE) score less than 24. sVCAM-1 was measured by ELISA assay. Beat-to-beat blood flow velocity (BFV) and cerebrovascular resistance (CVR = mean arterial pressure / BFV) in the middle cerebral artery were assessed at rest by transcranial Doppler ultrasound. RESULTS: sVCAM-1 concentrations were higher among participants with an MMSE score <24 versus ≥24 (1,201±417 vs 1,122±494ng/mL). In regression models adjusted for sociodemographic characteristics and health conditions, increasing levels of sVCAM-1 were linearly associated with higher resting CVR (p = .006) and lower performance on the Hopkins Verbal Learning Memory (immediate recall and delayed recall) and adjusted TMT B tests (p < .05). Higher levels of sVCAM-1 were also associated with global cognitive impairment on the MMSE (odds ratio = 3.9; 95% confidence interval: 1.4-10.9; p = .011). CONCLUSIONS: In this cohort of elderly participants, we observed a cross-sectional association between elevated sVCAM-1 levels and both cognitive impairment and increased cerebrovascular resistance. Longitudinal studies are needed to determine whether elevated sVCAM-1 is a cause or consequence of cerebrovascular damage.
Authors: Brenda R Chen; Mariel G Kozberg; Matthew B Bouchard; Mohammed A Shaik; Elizabeth M C Hillman Journal: J Am Heart Assoc Date: 2014-06-12 Impact factor: 5.501
Authors: Farzaneh A Sorond; Jorge M Serrador; Richard N Jones; Michele L Shaffer; Lewis A Lipsitz Journal: Ultrasound Med Biol Date: 2008-10-02 Impact factor: 2.998
Authors: Jamaji C Nwanaji-Enwerem; Marie-Abele Bind; Lingzhen Dai; Youssef Oulhote; Elena Colicino; Qian Di; Allan C Just; Lifang Hou; Pantel Vokonas; Brent A Coull; Marc G Weisskopf; Andrea A Baccarelli; Joel D Schwartz Journal: Toxicol Sci Date: 2017-07-01 Impact factor: 4.849
Authors: Carla R Schubert; Mary E Fischer; A Alex Pinto; Adam J Paulsen; Yanjun Chen; Guan-Hua Huang; Barbara E K Klein; Michael Y Tsai; Natascha Merten; Karen J Cruickshanks Journal: Neurol Sci Date: 2022-09-17 Impact factor: 3.830
Authors: Jan K Nowak; Irena Wojsyk-Banaszak; Edyta Mądry; Andrzej Wykrętowicz; Patrycja Krzyżanowska; Sławomira Drzymała-Czyż; Agata Nowicka; Andrzej Pogorzelski; Ewa Sapiejka; Wojciech Skorupa; Mariusz Szczepanik; Aleksandra Lisowska; Jaroslaw Walkowiak Journal: Lung Date: 2017-06-23 Impact factor: 2.584
Authors: Jérôme Robert; Emily B Button; Sophie Stukas; Guilaine K Boyce; Ebrima Gibbs; Catherine M Cowan; Megan Gilmour; Wai Hang Cheng; Sonja K Soo; Brian Yuen; Arvin Bahrabadi; Kevin Kang; Iva Kulic; Gordon Francis; Neil Cashman; Cheryl L Wellington Journal: Mol Neurodegener Date: 2017-08-22 Impact factor: 14.195